Interferon beta-1a in primary progressive multiple sclerosis

There is currently no disease-modifying treatment proven to be of efficacy in primary progressive multiple sclerosis (PPMS). However, a number of therapeutic trials have recently been specifically designed for this group. These include a randomised controlled trial of interferon beta-1a which is dis...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the neurological sciences 2003-02, Vol.206 (2), p.215-216
Main Authors: Leary, Siobhan M, Thompson, Alan J
Format: Article
Language:English
Subjects:
Adjuvants, Immunologic - therapeutic use
Adolescent
Adult
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Disability Evaluation
Disease Progression
Dose-Response Relationship, Drug
Follow-Up Studies
Glatiramer Acetate
Humans
Interferon beta-1a
Interferon beta-1b
Interferon-beta - therapeutic use
Magnetic Resonance Imaging
Medical sciences
Middle Aged
Mitoxantrone - therapeutic use
Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis
Multiple Sclerosis, Chronic Progressive - drug therapy
Neurology
Neuroprotective Agents - therapeutic use
Peptides - therapeutic use
Primary progressive multiple sclerosis
Riluzole - therapeutic use
Therapeutics
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:There is currently no disease-modifying treatment proven to be of efficacy in primary progressive multiple sclerosis (PPMS). However, a number of therapeutic trials have recently been specifically designed for this group. These include a randomised controlled trial of interferon beta-1a which is discussed here. It is hoped that therapeutics in primary progressive multiple sclerosis will continue to expand and effective therapeutic agents will be developed.
ISSN:0022-510X
DOI:10.1016/S0022-510X(02)00350-7